Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab SC prolonged maintenance versus observation in relapsed or refractory indolent non-Hodgkin lymphoma
2010-023407-95Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in indolent lymphoma, follicular lymphoma (FL), Waldenström macroglobulinemia (WM) and 2 more comparing Prolonged rituximab maintenance with Observation only (2 arms). Primary endpoint: Progression-free survival after randomization. Started Jul 2011; status: completed.
02
Drugs
rituximab
03
Conditions
indolent lymphomafollicular lymphoma (FL)Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2010-023407-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023407-95.